Researchers published a Nature Communications study describing bioengineered viral vectors that enable in vivo RNA editing in macrophages to treat sepsis. The chemogenetic system allows targeted modulation of macrophage pathways within living organisms, producing therapeutic effects in preclinical sepsis models. The platform combines vector engineering and RNA editing modalities to reprogram innate immune cells — an approach with potential beyond sepsis for inflammatory and infectious diseases. For biotech developers, the work highlights translational feasibility of delivered RNA-editing tools in immune effector cells and identifies challenges for safety, delivery specificity, and regulatory pathways.